Replies to post #123708 on Biotech Values

[genisi]

...how hard is it for Tasigna to make inroads against Gleevec, even though Tasigna showed statsig superiority to Gleevec in randomized phase-3 trials...

The same goes for BMY’s Sprycel with a note that it was approved in first-line CML late last year and a few months after Tasigna did. I still think the same as posted in #msg-51465496.